Brief: Sarepta Announces FDA Acceptance Of Sndas For Amondys 45® And Vyondys 53®
30/06/2026 13:36
BRIEF-Sarepta Announces FDA Acceptance Of Sndas For Amondys 45® And Vyondys 53® June 30 (Reuters) - Sarepta Therapeutics Inc SRPT.O:
SAREPTA ANNOUNCES FDA ACCEPTANCE OF SNDAS FOR AMONDYS 45® AND VYONDYS 53®
SAREPTA THERAPEUTICS - FDA SETS PDUFA TARGET ACTION DATE OF FEBRUARY 28, 2027
Source text: ID:nBw1dNBN0a
Further company coverage: SRPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sarepta Therapeutics
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure